NASDAQHealth CareHealth Information ServicesSnapshot 2026-07-23
Reading HQY? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
HQY represents a durable compounder with a focus on revenue and earnings growth. The current thesis is intact, supported by recent strong financial results and management's clear targets for the upcoming fiscal year.
The market appears to have a neutral valuation stance on HQY, with expectations slightly below what management has communicated. The stock is priced with a low fragility tier, indicating that current performance is justified but leaves little room for error.
Management is on track to meet its revenue and earnings targets for FY 2027, with strong recent performance supporting this trajectory. However, there is an elevated risk due to the potential for sector peers to miss earnings, which could impact HQY's momentum.
The future performance of HQY is closely tied to the results of sector bellwethers like VEEV, BTSG, and TEM. If these companies continue to perform well, it could provide a favorable backdrop for HQY, while any negative shifts could pose challenges.
In the next 1 to 3 years, HQY's performance will depend on its ability to maintain growth amidst sector volatility. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. This improvement is driven by the latest earnings beat, which indicates strong financial performance and supports the thesis that the reasons to own the stock remain intact. There are no current threats noted that would weaken this outlook.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Meeting this growth target shows HealthEquity is on track for its FY 2027 revenue goal. It confirms strong demand for HSAs.
Confirms:Q2 revenue growth is 7% or higher compared to Q2 2025.
Disproves:Q2 revenue growth is below 7% compared to Q2 2025.
Why it matters: Reaching this target shows strong performance. It also supports the FY 2027 outlook.
Confirms:Adjusted EBITDA was at least $164.5 million.
Disproves:Adjusted EBITDA was less than $164.5 million.
Why it matters: Hitting this revenue target shows strong growth and management's effectiveness. It reflects ongoing demand for HSAs.
Confirms:Revenue reported for Q1 FY 2027 exceeds $354.6 million, on track for the annual target.
Disproves:Revenue falls below $1.41 billion for FY 2027, indicating weaker growth.
Why it matters: Hitting this target shows how well HealthEquity operates. It also supports its growth plans.
Confirms:Adjusted EBITDA for Q2 is within the $625M-$633M range.
Disproves:Adjusted EBITDA for Q2 falls below $625M.
Why it matters: Net income per share is a key measure of profitability. A drop indicates financial stress.
Confirms:Net income per diluted share reported at or above $0.82.
Disproves:Net income per diluted share falls below $0.82.
Why it matters: Meeting this EPS target shows strong earnings growth. It matches management's expectations.
Confirms:EPS reported at or above $0.82.
Disproves:EPS reported below $0.82.
Why it matters: This metric shows profit and growth. It confirms that management is positive about the future.
Confirms:Net income per diluted share for Q2 is within the $2.88-$2.95 range.
Disproves:Net income per diluted share for Q2 is below $2.88.
Why it matters: Better performance in the sector could help HealthEquity grow more.
Confirms:Sector performance improves to better than -1% over the next 60 days.
Disproves:Sector performance worsens beyond -2% over the next 60 days.
Why it matters: Growth under 19% may mean less customer engagement. It could also show less account activity.
Confirms:HSA Assets growth reported below 19% year over year.
Disproves:HSA Assets growth exceeds 19% year over year.
Why it matters: New buybacks show that management believes in the company's value and future cash flow.
Confirms:Look for news of share buybacks totaling at least $100 million in the next quarter.
Disproves:No news of share buybacks in the next quarter.
